Kelly Dooley, MD

CRS:

JHU

Role:

Investigators

Position:

CRS Leader

Email:

kdooley1@jhmi.edu

Dr. Dooley is an Associate Professor of Medicine, Pharmacology, and Molecular Sciences at Johns Hopkins University School of Medicine, with appointments in the Divisions of Clinical Pharmacology and Infectious Diseases. She is also a faculty member at the Center for Clinical Global Health Education.

Dr. Dooley has an HIV outpatient practice and attends on the inpatient HIV service. Her research focuses on tuberculosis therapeutics with an emphasis on Phase I or II clinical trials of new or existing TB drugs and treatment of HIV/TB co-infection. She is Principal Investigator or Protocol Chair for several clinical trials involving TB drugs for drug-sensitive TB or drug-resistant TB and involved in the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group, and IMPAACT networks. She has a special interest in optimizing TB drugs for special populations, including children and pregnant women.

Dr. Dooley received her MD from Duke University, and completed residency training in internal medicine and an infectious diseases fellowship at Johns Hopkins School of Medicine. She is board certified in internal medicine and infectious diseases.

  • Vice-chair, ACTG Tuberculosis TSG (Dec 2017-Nov 2019)
  • Chair, ACTG TB Meningitis Working Group (Aug 2017)
  • Member, ACTG Tuberculosis TSG and IMPAACT TB Scientific Committee (Dec 2015)
  • Pharmacologist, Tuberculosis Transformative Science Group (Dec 2015-17)
  • Protocol vice-chair, IMPAACT P2005
  • Protocol vice-chair, ACTG 5384
  • Protocol co-chair, ACTG 5343, ACTG 5312
  • Protocol vice chair IMPAACT 2001
  • Protocol Team Member ACTG 5338, ACTG 5300, IMPAACT 1108, 5349, 5373
  • TB TSG Steering Committee 2017-present
  • Clinical Pharmacology Analytical Group (CPAG) 2015-present

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More